Protocol Ledger

NCT04205630 · Phase II · COMPLETED

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

Interventional Phase II clinical trial protocol NCT04205630 sponsored by Byondis in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-05-28 Enrollment: 64 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04205630
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)64 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04205630
Protocol FieldVerified Registry Value
NCT IdentifierNCT04205630
Consolidated Lead SponsorByondis
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment64 participants (ACTUAL)
Registered Start Date2020-05-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04205630
Hospital Research SiteLocationSite Profile
Yale Cancer Center and Smilow Cancer HospitalNew Haven, CTOpen Hospital Dossier ->
National Cancer Centre SingaporeSingapore, SingaporeOpen Hospital Dossier ->
Seoul National University Bundang HospitalSeongnam-si, South KoreaOpen Hospital Dossier ->
Seoul National University HospitalSeoul, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI